Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 7—July 2009
Research

Relapse Associated with Active Disease Caused by Beijing Strain of Mycobacterium tuberculosis1

William J. BurmanComments to Author , Erin E. Bliven, Lauren S. Cowan, Lorna Bozeman, Payam Nahid, Lois Diem, Andrew Vernon, and for the Tuberculosis Trials Consortium
Author affiliations: Denver Public Health, Denver Colorado, USA (W.J. Burman); University of Colorado at Denver Health Sciences Center, Denver (W.J. Burman); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.E. Bliven, L. Cowan, L. Bozeman, L. Diem, A. Vernon); The University of California, San Francisco, California, USA (P. Nahid)

Main Article

Table 1

Characteristics of case-patients and controls, Tuberculosis Trials Consortium Study 22*

Characteristic Case-patients (treatment failure or relapse), n = 64† Controls (patients cured), n = 296† Odds ratio (95% confidence interval) p value
Demographic
Age, y, mean (SD) 42 (13) 44 (14) 1.0 (0.97–1.01) 0.51
Men
54 (84)
214 (72)
2.1 (1.0–4.3)
0.05
Treatment
Rifapentine, 1×/wk 40 (63) 151 (51) 1.6 (0.9–2.8) 0.10
Rifampin, 2×/wk
24 (37)
145 (49)


Ethnic origin
Non-Hispanic white 22 (34) 43 (15) 3.1 (1.7–5.7) 0.0002
Non-Hispanic black 25 (39) 127 (43) 0.9 (0.5–1.5) 0.57
Hispanic 9 (14) 71 (24) 0.5 (0.2–1.1) 0.08
Asian–Pacific Islander 6 (9) 45 (15) 0.6 (0.2–1.4) 0.23
Native American
2 (3)
10 (3)
0.9 (0.2–4.3)
0.92
Birthplace
United States or Canada 48 (75) 200 (68) 1.4 (0.8–2.7) 0.24
Mexico 5 (8) 36 (12) 0.6 (0.2–1.6) 0.32
Europe 2 (3) 4 (1) 2.4 (0.4–13.1) 0.31
Southeast Asia 2 (3) 6 (2) 1.6 (0.3–7.9) 0.59
Western Pacific 4 (6) 33 (11) 0.5 (0.2–1.6) 0.24
Other
3 (5)
17 (6)
0.8 (0.2–2.8)
0.74
Baseline clinical features
Fever 50/62 (81) 166/289 (57) 3.1 (1.6–6.0) 0.0007
Sweats 42/63 (67) 162/287 (56) 1.5 (0.9–2.7) 0.14
Cough 61 (95) 256/294 (87) 3.0 (0.9–10.1) 0.06
Underweight‡ 38 (59) 82 (28) 3.8 (2.2–6.7) <0.0001
Sputum smear positive
55 (86)
193/292 (66)
3.1 (1.5–6.6)
0.002
Baseline chest radiographic features
Cavitation 54 (84) 146/287 (51) 5.2 (2.6–10.6) <0.0001
Bilateral pulmonary involvement
50 (78)
155/293 (53)
3.2 (1.7–6.0)
0.0002
Two-month sputum analysis
Smear positive 16 (25) 30/285 (11) 2.8 (1.4–5.6) 0.002
Culture positive
33 (54)
48/267 (18)
5.4 (3.0–9.7)
<0.0001
Mycobacterium tuberculosis lineage/family
East Asian/Beijing 15 (23) 42 (14) 1.9 (0.9–3.6) 0.07
Euro-American 47 (73) 221 (75) 0.9 (0.5–1.7) 0.84
Indo-Oceanic 0 25 (8.5) 0.08 (0.01–1.4) 0.01
East African 1 (1.6) 3 (1.0) 1.6 (0.16–15.1) 0.54
Unclassified lineage 1 (1.6) 5 (1.7) 0.9 (0.11–8.04) 1.00

*The Tuberculosis Trials Consortium Study enrolled patients during 1995–1998. Participants in the case–control study were selected from among 1,004 HIV-infected participants.
†Except for age, values are no. (%) or no. positive/no. tested (%).
‡Less than 10% below ideal bodyweight at diagnosis.

Main Article

1This study was presented in part at the 2008 International Conference of the American Thoracic Society, May 16–21, 2008, Toronto, Ontario, Canada.

Page created: November 08, 2010
Page updated: November 08, 2010
Page reviewed: November 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external